Is it legal to buy semaglutide labeled “research use only”? FDA’s statements and warning letters
Is it legal to buy semaglutide labeled for research use only?
FDA’s statements in this index address sellers, not buyers: FDA states it has warned companies that sold unapproved semaglutide, tirzepatide, retatrutide, survodutide or mazdutide falsely labeled “for research purposes” or “not for human consumption” directly to consumers with dosing instructions (FDA page current as of October 1, 2026). As of Nov 15, 2026, 15 FDA warning letters in this index quote that kind of labeling, 13 of them naming semaglutide.
This page is not legal advice. It lists FDA’s statements and letters.
The table below also includes letters naming retatrutide, cagrilintide or another investigational GLP-1 ingredient (26 letters in all). 21 name retatrutide, which FDA states cannot be used in compounding under federal law.
FDA’s statements
- Oct 1, 2026: FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law and are not components of FDA-approved drugs. FDA states it has warned telehealth companies for marketing unapproved drugs such as retatrutide, API distributors for selling retatrutide and other GLP-1 drugs to compounders, and outsourcing facilities for repackaging retatrutide. Source: FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- Oct 1, 2026: FDA states it has warned companies that sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide falsely labeled “for research purposes” or “not for human consumption,” sold directly to consumers with dosing instructions. Source: FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
FDA’s page does not date each paragraph; the date shown is the page’s “content current as of” date.
The letters
| Later letters FDA lists | Letter | ||||
|---|---|---|---|---|---|
| Aug 24, 2026 | TXP Innovations LLC dba Tex Peptides | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Aug 24, 2026 | Royal Peptides LLC | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Aug 24, 2026 | NuScience Peptides LLC | Unapproved New Drugs/Misbranded | Semaglutide, Retatrutide, Survodutide, Mazdutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Aug 24, 2026 | Peptide Partners LLC | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Aug 24, 2026 | Peak Performance Peptides | Unapproved New Drugs/Misbranded | Semaglutide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Mar 31, 2026 | Prime Sciences | Unapproved New Drugs Sold Over the Internet | Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, Mazdutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Mar 31, 2026 | Mile High Compounds LLC | Unapproved New Drugs Sold Over the Internet | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Mar 31, 2026 | Lovega LLC dba Pink Pony Peptides | Unapproved New Drugs Sold Over the Internet | Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Mar 31, 2026 | Gram Peptides | Unapproved New Drugs Sold Over the Internet | Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Mar 31, 2026 | PekCura Labs | Unapproved New Drugs Sold Over the Internet | Cagrilintide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jan 20, 2026 | GenoGenix LLC | Compounding Pharmacy/Adulterated Drug Products | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Dec 8, 2025 | Darmerica, LLC | CGMP/Active Pharmaceutical Ingredient (API)/Adulterated/Misbranded | Retatrutide, Cagrilintide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 10, 2025 | motionpharmacy.com | Unapproved New Drug/Misbranded | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Amazing Meds | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | GenLabMeds | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | MedClub by Dr. Jenn | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | GLP-1 Solution | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | ASN-LABS | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | EA WORKS Limited Liability Company dba Trust Labs | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 26, 2025 | USApeptide.com | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Dec 10, 2024 | Prime Vitality, Inc. dba Prime Peptides | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Dec 10, 2024 | Swisschems | Unapproved New Drugs/Misbranded | Semaglutide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Dec 10, 2024 | Xcel Research LLC | Unapproved New Drugs/Misbranded | Semaglutide, Retatrutide, Cagrilintide, Survodutide, Mazdutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Dec 10, 2024 | Summit Research Peptides | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, Mazdutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 7, 2024 | US Chem Labs | CGMP/Finished Pharmaceuticals/Adulterated | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 7, 2024 | Synthetix Inc. DBA Helix Chemical Supply | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
Common questions
Can retatrutide be compounded?
FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law and are not components of FDA-approved drugs (FDA page content current as of October 1, 2026).
Which sellers of “research use only” GLP-1s got FDA warning letters?
15 letters in this index quote research-use or not-for-human-consumption labeling as of Nov 15, 2026. Each is in the table with the recipient, date and FDA subject line.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA warning letters (fda.gov full-text search)
- FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Records last pulled Nov 15, 2026. Every entry links to the original public record.